Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

Genitourinary CancerFurther Publications

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Eur J Cancer

Shore N, Morgans AK, Boegemann M, Gallagher E, Paracha N, Serafini P, Pushkarna D, Pourrahmat MM, Kurt M, Abrams KR

doi: 10.1016/j.ejca.2025.115513

Genitourinary Cancer

Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data

Prostate Cancer Prostatic Dis

Shore N, Morgans AK, Paracha N, Gallagher E, Thom H, Aceituno D, Orishaba P, Stefani S, Trinh QD, Wallis CJD, Abrams KR, Boegemann M

doi: 10.1038/s41391-025-01054-8

Genitourinary Cancer

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Ann Oncol

Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, Shevrin DH, Cooney MM, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney CJ

doi: 10.1016/j.annonc.2025.08.004

Genitourinary Cancer

Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial

Eur Urol

Grimm MO, Smith M, Hussain M, Saad F, Fizazi K, Littleton N, Paracha N, Srinivasan S, Verholen F, Tombal B

doi: 10.1016/j.eururo.2025.05.037

Genitourinary Cancer

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

Eur Urol

Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad AA

doi: 10.1016/j.eururo.2025.12.021

Genitourinary Cancer

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes

Ann Oncol

Olmos D, Lorente D, Jambrina A, Tello Velasco D, Ovejero-Sánchez M, Gonzalez-Ginel I, Romero-Laorden N, Nunes-Carneiro D, Balongo M, Gutierrez-Pecharromán AM, Llácer C, Prieto JD, Pérez-Argüelles D, Alberca Del Arco F, Miguel-Masiá J, Ruiz-Vico M, Santos R, Esteban-Villarrubia J, Gonzalez-Billalabeitia E, Jürgens A, Capone C, Trevisan M, Van Sanden S, Stulnig G, Hernández D, López-Casas PP, A Rodriguez-Antolin, Castellano DE, Herrera-Imbroda B, Castro E

doi: 10.1016/j.annonc.2025.05.534

Genitourinary Cancer

Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide

Prostate

Martínez Osorio CA, Sopeña Sutil R, Vilaseca Cabo A, Linares Espinós E, Ramírez Backhaus M, Gómez Rivas J, Costa Planells M, Martinez Breijo S, Picola Brau N, Domínguez Esteban N, Muñoz Rodríguez J, Sanchís Bonet A, Guijarro Cascales A, Beamud Cortés M, Servian Vives P, de la Morena Gallego JM, Pérez Márquez M, García Sanz M, Ramón Alemán J, Zamora Horcajada Á, Rodríguez Part V, Hassi Roman M, Rodriguez Concha C, Rios González E, de Pablos-Rodríguez P

doi: 10.1002/pros.70040

Genitourinary Cancer

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study

Urol Oncol

Rinderknecht E, Bielstein G, Cathomas R, Schlack K, Bastian JLD, Darr C, Unland-Gies D, Kappler P, Paffenholz P, Richter J, Müller M, Seitz AK, Steinestel J, Heidegger I, Burger M, Breyer J, Schnabel MJ

doi: 10.1016/j.urolonc.2026.111028

Genitourinary Cancer

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Prostate Cancer Prostatic Dis

Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M

doi: 10.1038/s41391-025-01067-3

Related content

Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis

Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes

Prostate-Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide

Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective study

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study